What MOS show in the lab's own samples
MOS grow organoids in a miniaturized, pipetteable format, so the assays you run on organoids carry over to MOS. Each published study is one example of what MOS can do, not the limit.
A single MOS with organoids growing inside, imaged by fluorescence.
Publications on MOS
Five peer-reviewed papers and thirteen conference abstracts and posters, 18 in all.
Functional precision medicine using MicroOrganoSpheres for treatment response prediction in advanced colorectal cancer
Gobits R, Schleußner N, Oliver GR, et al. JCO Precision Oncology, 2026. doi.org/10.1200/PO-25-00501
MicroOrganoSphere technology to advance drug screening in neuroblastoma precision medicine
Schoonbeek MC, Amo-Addae V, Koomen M, et al. EJC Paediatric Oncology, 2026. doi.org/10.1016/j.ejcped.2026.100534
Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells
Gurrea-Rubio M, Wu Q, Amin MA, et al. Cancer Immunology, Immunotherapy, 2024. doi.org/10.1007/s00262-023-03578-1
Patient-derived micro-organospheres enable clinical precision oncology
Ding S, Hsu C, Wang Z, et al. Cell Stem Cell, 2022. doi.org/10.1016/j.stem.2022.04.006
Rapid tissue prototyping with micro-organospheres
Wang Z, Boretto M, Millen R, et al. Stem Cell Reports, 2022. doi.org/10.1016/j.stemcr.2022.07.016
Functional precision medicine in advanced colorectal cancer
Gobits R, et al. AACR Annual Meeting 2026, abstract 4184.
Near-real-time detection of epithelial killing supports BiTE evaluation directly from fresh NSCLC and breast tumors
Graham DM, Contreras-Ruiz L, Rivera M, et al. AACR-IO 2026, abstract B056. Cancer Immunology Research. doi.org/10.1158/2326-6074.IO2026-B056
A patient-derived 3D MicroOrganoSpheres (MOS) platform to evaluate functional potency of autologous TILs in non-small cell lung cancer (NSCLC)
Contreras-Ruiz L, Graham D, Layton J, et al. AACR-IO 2026, abstract A067. Cancer Immunology Research. doi.org/10.1158/2326-6074.IO2026-A067
Functional precision medicine using MicroOrganoSpheres for treatment response prediction in advanced colorectal cancer
Köhler B, Gobits R, Schleußner N, et al. ESMO Congress 2025, poster 821P.
Predicting colorectal cancer patient response to neoadjuvant chemotherapy using the MicroOrganoSphere (MOS) platform
Gobits R, Schleußner N, Oliver G, et al. ASCO 2025, abstract e15518. Journal of Clinical Oncology. doi.org/10.1200/JCO.2025.43.16_suppl.e15518
Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC)
Graham D, Rupprecht G, Watlington W, et al. ASCO 2023, abstract 1107. Journal of Clinical Oncology. doi.org/10.1200/JCO.2023.41.16_suppl.1107
Patient-derived MicroOrganoSpheres (MOS) enable precision clinical decision-making for multiple myeloma patients
Xi R, Wang X, Moseley R, et al. AACR 2023, abstract 3412. Cancer Research. doi.org/10.1158/1538-7445.AM2023-3412
A novel and rapid patient-derived organoid breast cancer platform for precision medicine
Graham DM, Rupprecht G, Bankaitis ED, et al. AACR 2023, abstract 192. Cancer Research. doi.org/10.1158/1538-7445.AM2023-192
Identifying targeted therapy combination for refractory colorectal cancer using micro-organospheres
Ding S, Kanikarla Marie P, Zhang R, et al. ASCO GI 2023, abstract 27. Journal of Clinical Oncology. doi.org/10.1200/JCO.2023.41.4_suppl.27
Micro-organospheres retain patient tumor microenvironment for precision immuno-oncology
Ding S, Natesh NR, Spiller K, et al. ASCO 2022, abstract 2573. Journal of Clinical Oncology. doi.org/10.1200/JCO.2022.40.16_suppl.2573
Microorganospheres as a novel precision oncology platform in colorectal cancer
Hsu C, Wang Z, Oh S, et al. ASCO GI 2022, abstract 149. Journal of Clinical Oncology. doi.org/10.1200/JCO.2022.40.4_suppl.149
Patient-derived micro-organospheres (MOS) recapitulate tumor microenvironment and heterogeneity for precision oncology
Ding S, Wang Z, Hsu C, et al. ESMO 2021, abstract 3O. Annals of Oncology. doi.org/10.1016/j.annonc.2021.08.281
Micro-organospheres as a novel precision oncology platform in colorectal cancer
Hsu CT, Wang Z, Oh S, et al. ESMO 2021, abstract 1782P. Annals of Oncology. doi.org/10.1016/j.annonc.2021.08.1725
Read the application notes
The DILI application note and a summary of the tissues and readouts used with MOS.